ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2719

Urinary Angiostatin As Alternative To Biopsy In  lupus Nephritis Patients Among Egyptian

Shereen Algergawy1, Osama Alshaar2 and Rania Zakaria3, 1rheumatology and rehabilitation, associate prof at benha university faculty of medicine rheumatology and rehabilitation department Egypt, cairo, Egypt, 2clinical pathology, benha university faculty of medicine, benha, Egypt, 3pathology, benha university faculty of medicine, benha, Egypt

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Lupus nephritis (LN) is one of the most frequent manifestations of SLE and can be present in 60% of SLE patients.  Kidney biopsy remains the basis of LN diagnosis . There is urgent need to identify biomarkers that  alternative  to renal pathology in lupus.

Aim :To study urinary angiostatin in SLE  and investigate their possible role as indicative of renal involvement to be used as alternative to biopsy .

Methods: Angiostatin levels were measured in urine samples from 45 lupus patients and 14 healthy volunteers, renal biopsy was obtained from all patients

Results: SLE  patients had elevated urinary angiostatin as compared to controls (P < 0.001). Levels of urinary angiostatin were higher in patients with an  active  LN (lupus nephritis ) than those with  inactive   LN (P < 0.001). In patients with LN urinary angiostatin correlated with the renal score of the Systemic Lupus Erythematosus Disease Activity Index. Urinary angiostatin levels varied significantly and there is significant positive correlation (P <0.05) levels with the activity  and choronicty scores of the examined renal biopsies among the histopathological groups.

Conclusion: Urinary angiostatin is potentially useful markers of lupus activity. urinary angiostatin able to differentiate  patients with active SLE from those with inactive disease .urinary levels are indicative of renal activity. Patients with Class IV lupus nephritis exhibited the highest levels of urinary angiostatin.Urinary angiostatin can be used as non invasive marker to detect renal involvement in lupus nephritis alternative to renal biopsy


Disclosure:

S. Algergawy,
None;

O. Alshaar,
None;

R. Zakaria,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-angiostatin-as-alternative-to-biopsy-in-lupus-nephritis-patients-among-egyptian/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology